Vimarsana
Biggest News Aggregation in the World

Page 4 - Combination Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Combination Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Combination Therapy Today - Breaking & Trending Today

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape - Vimarsana News

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

Third Line Treatment in Chronic GVHD - Vimarsana News

Third Line Treatment in Chronic GVHD

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss a complex chronic GVHD case post-allogeneic transplant. The panel explores third-line options, including belumosudil, ibrutinib, photopheresis, and clinical trials, emphasizing shared decision-making and the need for well-designed trials in guiding treatment decisions.

SOC Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies - Vimarsana News

SOC Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

Belumosudil for Treatment of Chronic GVHD - Vimarsana News

Belumosudil for Treatment of Chronic GVHD

The expert panel explores belumosudil's role in treating chronic GVHD after multiple systemic therapy lines. They discuss the ROCKstar trial, highlighting its overall response rates and real-world experiences.

"PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors agai" by Jay R. Perry, Benjamin Genenger et al. - Vimarsana News

"PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors agai" by Jay R. Perry, Benjamin Genenger et al.

Cutaneous squamous cell carcinoma (cSCC) is a very common skin malignancy with poor prognosis for patients with locally advanced or metastatic cSCC (mcSCC). PI3K/AKT/mTOR and cell cycle signalling pathways are often dysregulated in mcSCC. A combination drug approach has been theorised to overcome the underwhelming clinical performance of targeted inhibitors as single agents. This study investigates the potential of targeted inhibition of the p110α−subunit of PI3K with PIK-75 or BGT226 (P13Ki), and of CDK1/2/5/9 with dinaciclib (CDKi) as single agents and in combination. The patient−derive...

Source: uow.edu.au